WALTHAM, Mass.--(BUSINESS WIRE)--In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.
“We take a very multi-faceted, consultative approach to achieving best practices and high-reliability in glucose management,” says Raymie McFarland, Vice President of Quality Initiatives at Glytec. “Our attention to clinical practice change and quality improvement is proven to reduce the risks and costs associated with glycemic variability, hypoglycemia and hyperglycemia.”
Less-than-optimal glucose management in the acute care setting is shown to have a dramatic impact on clinical and financial outcomes. A recent study by AdventHealth Orlando (formerly known as Florida Hospital System) observed that hospitalized patients who experience severe hypoglycemia incur $10,405 of excess cost, a 61.5% higher readmission rate and a 6.6-day longer stay.
“We’re able to combat the underlying issues,” says McFarland. “We have an abundance of real-world, published evidence showing that our comprehensive systems approach to glucose management reduces severe hypoglycemia by as much as 99.8%, 30-day readmissions by 36 to 68%, and lengths of stay by up to 3.2 days, leading to overall cost savings as high as $20,000 per licensed bed.”
Among key results on the AdventHealth Waterman storyboard were a 96.8% improvement in incidence of severe hypoglycemia with the root cause of insulin stacking and 87.0% improvement in incidence of severe hypoglycemia with the root cause of failure to adjust insulin doses. Among key results on the Sentara Virginia Beach General Hospital storyboard was a 277% increase in the number of insulin-requiring patients whose subcutaneous therapy was delivered using basal-bolus-correction best practices with eGMS®.
About Glytec
Founded in 2006, Glytec is the pioneer of digital therapeutics, improving lives of people with diabetes through insulin optimization technologies and services. The company’s patented eGlycemic Management System® is the only FDA-cleared software-as-a-medical-device (SaMD) platform purpose built to support best practices in insulin therapy across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several comprehensive programs combining evidence-based decision support technologies with expert professional services proven to reduce hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.
